Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art-Reference-Cited by-同舟云学术

Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art

Published:2023-02 Issue: Volume:Volume 10 Page:181-191
ISSN:2253-5969
Container-title:Journal of Hepatocellular Carcinoma
language:en
Short-container-title:JHC

Author:

Laschtowitz Alena,Roderburg Christoph,Tacke Frank^ORCID,Mohr Raphael

Publisher

Informa UK Limited

Subject

General Medicine

Reference50 articles.

1. Advances in systemic therapy for the first-line treatment of unresectable HCC

2. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

3. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

4. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

5. OncologyPRO. Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase; 2023. Available from: https://oncologypro.esmo.org/meeting-resources/esmo-congress/camrelizumab-c-plus-rivoceranib-r-vs.-sorafenib-s-as-first-line-therapy-for-unresectable-hepatocellular-carcinoma-uhcc-a-randomized-phase. Accessed February 2, 2023.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma;Biomedicines;2024-08-07

2. Decoding the Prognostic Significance and Therapeutic Implications of Inflammation-Based Scores in Hepatocellular Carcinoma: A Comprehensive Review;Cancers;2024-07-15

3. Prolongated and large dose of r-ATG relieves PD-L1 inhibitor-induced allograft rejection in liver transplant recipient;Hepatobiliary & Pancreatic Diseases International;2024-05

4. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives;Journal of Hematology & Oncology;2024-04-29

5. Neoadjuvant systemic therapy for hepatocellular carcinoma;Frontiers in Immunology;2024-03-01